Wayne Winegarden
Blog
Learn How Drug Price Controls Hurt Patients
Big Pharma Is Not Gouging Americans nor Driving Up Healthcare Costs
Whether it is Sanders vilifying pharmaceutical companies or Trump’s emphasis on imposing price controls, they both allege that drug spending is a primary driver of the nation’s rising healthcare costs. Even a cursory look at the data demonstrates their focus is misplaced. Let’s start with the national health expenditure data ...
Blog
Spending Watch
California’s FY2025-26 Budget Failed to Address the State’s Long-term Financial Risks
California’s FY2025-26 Budget Failed to Address the State’s Long-term Financial Risks Wayne Winegarden October 2025 Politicians too often assume that California’s fiscal health is synonymous with the state of its annual budget. When revenue growth is strong, the state is allegedly in a sound fiscal position. It is only when ...
Drug Prices
NEW BRIEF: New California Medi-Cal Restrictions Will Hurt Patients; Competition Key to Affordable, High-Quality Health Care
SACRAMENTO – As California prepares to restrict access to proven private health insurers for dual eligible Medicare and Medi-Cal patients, the Center for Medical Economics and Innovation at the Pacific Research Institute – the nonpartisan, California-based, free market think tank – today released a new brief showing that expanding competition—not ...
Commentary
The Administration Risks Drug Shortages That Will Cost Patients Dearly
Judged by its actions, the Trump Administration supports drug shortages. Clearly, this is not the President’s stated goal, but it is the inevitable result of his policies including his proposed drug tariffs and most favored nation (MFN) policies. Read the op-ed here.
Blog
The fast food minimum wage hike continues to kill jobs
Governor Newsom Protests Too Much – the Minimum Wage Increase Did Destroy Jobs
As the New York Post reported, Newsom’s deputy director of communications Tara Gallegos disputed the findings of the piece, pointing out to Fox News Digital that the research paper was linked to the Hoover Institution, a public policy think tank she claimed has published “false or misleading information” about California’s ...
Blog
Read part 3 of a series on drug pricing
Regulations, Not Anticompetitive Actions, Are Obstructing Drug Competition
The flaws driving up costs across the broader health care landscape are also driving up the costs for innovative drugs. After all, pharmaceuticals are an integral component used in combination with the broader healthcare system. As a result, spending on medicines both influences and is influenced by the spending on ...
Blog
The U.S. Drug System Strikes a Reasonable Balance Between Incentivizing Innovation and Promoting Competition
The government explicitly grants innovators temporary market exclusivity to provide an opportunity for groundbreaking pharmaceutical companies to recover the costs of capital associated with developing novel treatments. This was one of the express purposes of past federal reform legislation, such as the Hatch-Waxman Act signed in 1984 and the Biologics ...
Blog
Read part 1 of a 3 part series on drug pricing
Conspiracies Aside, Drug Company Profits Are Average
Recently, the Federal Trade Commission (FTC) held its first of three listening sessions on the pharmaceutical market. The goal was to discuss reforms that will improve drug affordability by increasing “generic and biosimilar availability” and promoting “competition”. Achieving these goals is essential. The flaw of the first listening session is ...
Blog
Spending Watch
An Irresponsible FY2025-26 Budget All but Ensures Future Fiscal Crises
An Irresponsible FY2025-26 Budget All but Ensures Future Fiscal Crises Wayne Winegarden July 2025 Another fiscal year, another lost opportunity. In a June 2025 Spending Watch analysis, I lamented that Newsom was relying on gimmicks to close the current $12 billion budget deficit. The final budget the governor and legislative ...
Blog
The 340B Discounts Hospitals Receive Will Often Exceed Total Drug Prices in Europe
Table 1: PBM Fees and Rebates Can Exceed International Prescription Medicine Prices by As Much As 900% I previously highlighted how estimated rebates and fees PBMs receive for 10 commonly used brand medicines far exceed the total prices of those medicines in eight OECD countries (see Table 1). For example, ...
Learn How Drug Price Controls Hurt Patients
Big Pharma Is Not Gouging Americans nor Driving Up Healthcare Costs
Whether it is Sanders vilifying pharmaceutical companies or Trump’s emphasis on imposing price controls, they both allege that drug spending is a primary driver of the nation’s rising healthcare costs. Even a cursory look at the data demonstrates their focus is misplaced. Let’s start with the national health expenditure data ...
Spending Watch
California’s FY2025-26 Budget Failed to Address the State’s Long-term Financial Risks
California’s FY2025-26 Budget Failed to Address the State’s Long-term Financial Risks Wayne Winegarden October 2025 Politicians too often assume that California’s fiscal health is synonymous with the state of its annual budget. When revenue growth is strong, the state is allegedly in a sound fiscal position. It is only when ...
NEW BRIEF: New California Medi-Cal Restrictions Will Hurt Patients; Competition Key to Affordable, High-Quality Health Care
SACRAMENTO – As California prepares to restrict access to proven private health insurers for dual eligible Medicare and Medi-Cal patients, the Center for Medical Economics and Innovation at the Pacific Research Institute – the nonpartisan, California-based, free market think tank – today released a new brief showing that expanding competition—not ...
The Administration Risks Drug Shortages That Will Cost Patients Dearly
Judged by its actions, the Trump Administration supports drug shortages. Clearly, this is not the President’s stated goal, but it is the inevitable result of his policies including his proposed drug tariffs and most favored nation (MFN) policies. Read the op-ed here.
The fast food minimum wage hike continues to kill jobs
Governor Newsom Protests Too Much – the Minimum Wage Increase Did Destroy Jobs
As the New York Post reported, Newsom’s deputy director of communications Tara Gallegos disputed the findings of the piece, pointing out to Fox News Digital that the research paper was linked to the Hoover Institution, a public policy think tank she claimed has published “false or misleading information” about California’s ...
Read part 3 of a series on drug pricing
Regulations, Not Anticompetitive Actions, Are Obstructing Drug Competition
The flaws driving up costs across the broader health care landscape are also driving up the costs for innovative drugs. After all, pharmaceuticals are an integral component used in combination with the broader healthcare system. As a result, spending on medicines both influences and is influenced by the spending on ...
The U.S. Drug System Strikes a Reasonable Balance Between Incentivizing Innovation and Promoting Competition
The government explicitly grants innovators temporary market exclusivity to provide an opportunity for groundbreaking pharmaceutical companies to recover the costs of capital associated with developing novel treatments. This was one of the express purposes of past federal reform legislation, such as the Hatch-Waxman Act signed in 1984 and the Biologics ...
Read part 1 of a 3 part series on drug pricing
Conspiracies Aside, Drug Company Profits Are Average
Recently, the Federal Trade Commission (FTC) held its first of three listening sessions on the pharmaceutical market. The goal was to discuss reforms that will improve drug affordability by increasing “generic and biosimilar availability” and promoting “competition”. Achieving these goals is essential. The flaw of the first listening session is ...
Spending Watch
An Irresponsible FY2025-26 Budget All but Ensures Future Fiscal Crises
An Irresponsible FY2025-26 Budget All but Ensures Future Fiscal Crises Wayne Winegarden July 2025 Another fiscal year, another lost opportunity. In a June 2025 Spending Watch analysis, I lamented that Newsom was relying on gimmicks to close the current $12 billion budget deficit. The final budget the governor and legislative ...
The 340B Discounts Hospitals Receive Will Often Exceed Total Drug Prices in Europe
Table 1: PBM Fees and Rebates Can Exceed International Prescription Medicine Prices by As Much As 900% I previously highlighted how estimated rebates and fees PBMs receive for 10 commonly used brand medicines far exceed the total prices of those medicines in eight OECD countries (see Table 1). For example, ...
